These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 30388109)

  • 21. Patients with non-valvular atrial fibrillation on vitamin k antagonists or direct-acting oral anticoagulants: patients profile and long-term follow up outcomes.
    Sigismondi A; Camacho-Freire SJ; León-Jiménez J; Isasti-Aizpurva G; García-Lizana MD; Morgado-García de Polavieja JI; Caro-Fernández FJ; Roa-Garrido J; Navarro-Roldán F; Díaz-Fernández JF
    Arch Cardiol Mex; 2019; 89(4):382-392. PubMed ID: 31834326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
    Lamberts M; Gislason GH; Lip GY; Lassen JF; Olesen JB; Mikkelsen AP; Sørensen R; Køber L; Torp-Pedersen C; Hansen ML
    Circulation; 2014 Apr; 129(15):1577-85. PubMed ID: 24470482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study.
    Himmler S; Müller M; Ostwald D; Seddik A; Basic E; Hradetzky E
    Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):223-230. PubMed ID: 30295561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation.
    Sindet-Pedersen C; Staerk L; Lamberts M; Gerds TA; Berger JS; Nissen Bonde A; Langtved Pallisgaard J; Hansen ML; Torp-Pedersen C; Gislason GH; Bjerring Olesen J
    Heart; 2018 Jun; 104(11):912-920. PubMed ID: 29092916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation.
    Gallego P; Roldan V; Marín F; Romera M; Valdés M; Vicente V; Lip GY
    Thromb Haemost; 2013 Dec; 110(6):1189-98. PubMed ID: 24096615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute Ischemic Stroke Outcome and Preceding Anticoagulation: Direct Oral Anticoagulants Versus Vitamin K Antagonists.
    Tavares SF; Ferreira I; Chaves V; Flores L; Correia C; Almeida J; Fonseca L; Castro Chaves P
    J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104691. PubMed ID: 32067853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma C; Zint K; Elsaesser A; Bartels DB; Lip GY;
    Am J Med; 2015 Dec; 128(12):1306-13.e1. PubMed ID: 26239094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality of INR control and switching to non-Vitamin K oral anticoagulants between women and men with atrial fibrillation treated with Vitamin K Antagonists in Spain. A population-based, real-world study.
    García-Sempere A; Hurtado I; Bejarano-Quisoboni D; Rodríguez-Bernal C; Santa-Ana Y; Peiró S; Sanfélix-Gimeno G
    PLoS One; 2019; 14(2):e0211681. PubMed ID: 30753227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National Acute Stroke Israeli Survey [NASIS]).
    Schwammenthal Y; Bornstein N; Schwammenthal E; Schwartz R; Goldbourt U; Tsabari R; Koton S; Grossman E; Tanne D
    Am J Cardiol; 2010 Feb; 105(3):411-6. PubMed ID: 20102959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.
    Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP
    Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
    Hellfritzsch M; Husted SE; Grove EL; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A
    Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):187-194. PubMed ID: 27580086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of non-vitamin K oral anticoagulant treatment compared with warfarin in patients with non-valvular atrial fibrillation who develop acute ischemic stroke or transient ischemic attack: a multicenter prospective cohort study (daVinci study).
    Saji N; Kimura K; Tateishi Y; Fujimoto S; Kaneko N; Urabe T; Tsujino A; Iguchi Y;
    J Thromb Thrombolysis; 2016 Nov; 42(4):453-62. PubMed ID: 27207691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists.
    Sørensen R; Jamie Nielsen B; Langtved Pallisgaard J; Ji-Young Lee C; Torp-Pedersen C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jul; 3(3):151-156. PubMed ID: 28158553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early administration of non-vitamin K antagonist oral anticoagulants for acute ischemic stroke patients with atrial fibrillation in comparison with warfarin mostly combined with heparin.
    Nomura E; Ohshita T; Imamura E; Wakabayashi S; Kajikawa H; Hosomi N; Matsumoto M
    Circ J; 2015; 79(4):862-6. PubMed ID: 25736910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF.
    Haas S; Camm AJ; Bassand JP; Angchaisuksiri P; Cools F; Corbalan R; Gibbs H; Jacobson B; Koretsune Y; Mantovani LG; Misselwitz F; Panchenko E; Ragy HI; Stepinska J; Turpie AG; Sawhney JP; Steffel J; Lim TW; Pieper KS; Virdone S; Verheugt FW; Kakkar AK;
    Am Heart J; 2019 Jul; 213():35-46. PubMed ID: 31128503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project.
    Lip GY; Clementy N; Pericart L; Banerjee A; Fauchier L
    Stroke; 2015 Jan; 46(1):143-50. PubMed ID: 25424474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: A nationwide population-based study.
    Lee SR; Choi EK; Han KD; Cha MJ; Oh S; Lip GYH
    PLoS One; 2017; 12(12):e0189495. PubMed ID: 29261716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The neurologist's approach to cerebral infarct and transient ischaemic attack in patients receiving anticoagulant treatment for non-valvular atrial fibrillation: ANITA-FA study.
    Zapata-Wainberg G; Masjuan J; Quintas S; Ximénez-Carrillo Á; García Pastor A; Martínez Zabaleta M; Cardona P; Freijo Guerrero MM; Llull L; Benavente Fernández L; Castellanos Rodrigo M; Egido J; Serena J; Vivancos J;
    Eur J Neurol; 2019 Feb; 26(2):230-237. PubMed ID: 30153363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.